Supera编织型支架应用于股腘动脉病变短中期随访结果  

short-and mid-term outcomes of Supera interwoven nitinol stent for the treatment of femoropopliteal artery disease

作　　者：李梓伦[1] 王冕[1] 武日东[1] 黄侃 王慧[1] 刘云彦 胡作军[1] 姚陈[1] 常光其[1] Li Zilun;Wang Mian;Wu Ridong;Huang Kan;Wang Hui;Liu Yunyan;Hu Zuojun;Yao Chen;Chang Guangqi(National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases Division of Vascular Surgery First Affiliated Hospital,First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080)

机构地区：[1]血管疾病诊治技术国家地方(广东)联合工程实验室、中山大学附属第一医院血管外科,广州510080

出　　处：《中华血管外科杂志》2022年第3期187-190,共4页Chinese Journal of Vascular Surgery

基　　金：国家自然科学基金项目(81970416)。

摘　　要：目的评价Supera编织型支架治疗股腘动脉病变的短中期疗效。方法回顾性分析2016年12月至2021年8月中山大学附属第一医院血管外科收治的100例(102条患肢)采用Supera支架治疗的股腘动脉病变患者的临床资料。采用student’st检验比较手术前后踝肱指数(ABI)差异,采用Kaplan-Meier生存曲线分析随访时间超过12个月的患者的支架通畅率。结果本组共植入支架161枚,技术成功率100%。术后住院时间(5.78±6.92)d,无围术期严重并发症发生,所有患肢术后ABI均较术前改善,差异具有统计学意义(0.88±0.25比0.30±0.33,t=10.66,P<0.001)。97例患者(99条患肢)获得随访,随访时间(18.59±13.77)个月。随访期内,症状较术前改善者67例(69.1%),支架内狭窄30例(30.9%),截肢7例(7.2%),死亡12例(12.4%),无支架相关死亡。62条(62.6%)患肢随访时间超过12个月,术后3、6及12个月的一期通畅率分别为97.6%、87.8%和75.6%,二期通畅率分别为97.6%、95.1%和90.2%。结论Supera编织型支架治疗股腘动脉病变中短期疗效安全、有效。Objective To evaluate the short-and mid-term efficacy of Supera interwoven nitinol stent for the treatment of femoropopliteal artery disease.Methods Clinical data of 100 patients with 102 affected limbs with femoropopliteal artery disease who underwent implantation of Supera interwoven nitinol stent in the Department of Vascular Surgery,the First Affiliated Hospital of Sun Yat-sen University from December 2016 to August 2021 were analyzed retrospectively.Comparison of pre-and post-operative ankle-brachial index(ABI)was made using the student's t-test.Additionally,the Kaplan-Meier survival curve was used to calculate the primary and secondary patency rates for patients with at least one-year follow-up.Results A total of 161 stents were implanted with a success rate of 100%.The mean length of postoperative hospital stay was(5.78±6.92)days.No serious perioperative complication occurred.The ABI increased from 0.30±0.33 preoperatively to 0.88±0.25 postoperatively(t=10.66,P<0.001).Moreover,97 patients(99 limbs)were followed up for(18.59±13.77)months.69.1%(67/97)of patients were significantly improved.Besides,in-stent stenosis and amputation were observed in 30.9%(30/97)and 7.2%(7/97)of cases,respectively.The mortality rate was 12.4%(12/97)and no stent-related death happened.Furthermore,62(62.6%,62/99)limbs were followed up for over 12 months.The 3-,6-and 12-month primary patency rates were 97.6%,87.8%and 75.6%,respectively,and the secondary patency rates were 97.6%,95.1%and 90.2%,respectively.Conclusions The short-and mid-term efficacy of Supera interwoven nitinol stent for the treatment of femoropopliteal artery disease appears to be safe and effective.

关 键 词：下肢动脉硬化闭塞症 股腘动脉病变 支架植入术 Supera支架 治疗 

分 类 号：R654.4[医药卫生—外科学]